Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-01-25

FDA Approved: PHOTREXA CROSS-LINKING KIT — Supplemental Application (Glaukos Corporation)

View source ↗

Summary

The FDA approved a supplemental application for the Photrexa Cross-Linking Kit, including riboflavin 5-phosphate ophthalmic solution, used to perform corneal cr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PHOTREXA CROSS-LINKING KIT (Riboflavin 5-phosphate ophthalmic)
  • RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC (Riboflavin 5-phosphate ophthalmic)

Snippet

SUPPL AP for PHOTREXA CROSS-LINKING KIT (RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC)